National Eye Institute (NEI), Bethesda, Maryland, 20892, United States - 12 Jul `24National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases

National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases

Official title: National Ophthalmic Genotyping and Phenotyping Network, Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases

Status: Recruiting now

Description:

Background: The eyeGENE (Registered Trademark) program is a research resource for inherited eye conditions which includes genotypic and phenotypic data, imaging, and a corresponding biobank of DNA samples from people with a variety of eye diseases. Since 2007 this registry has been helping researchers learn more about the genetic sources for many inherited eye diseases. These findings helped them create better treatments. Now researchers want to expand eyeGENE (Registered Trademark) to include more people for certain eye diseases. Objective: To collect information and DNA samples for the study of eye diseases. • Primary objective --To expand the current eyeGENE (Registered Trademark) data repository with targeted participant accrual • Secondary objectives • To enhance recruitment for clinical trials and investigations in inherited eye diseases • To establish genotype-phenotype correlations for rare eye diseases Eligibility: People of any age with certain eye diseases. These can include aniridia; Best disease; blue-cone monochromacy; corneal dystrophy; and disorders of pigmentation, such as albinism. Relatives unaffected by the eye disease of interest may also be needed. Design: Researchers will select participants based on their diagnosis. The data may include images and test results from eye exams. Participants will provide a sample of saliva. They will receive a kit with written instructions. They will spit in a tube and mail it to the NIH. Participants may be asked to provide a blood sample. The blood may be drawn at the NIH or at a local clinic. The eyeGENE (Registered Trademark) repository will offer researchers data about the participants eye conditions. The data may include pictures of their eyes, results of the genetic testing, and history of other diseases. Researchers will be able to see data such as age and gender, but they will not see names, dates of birth, or contact information.

Who can take part: ages 1 Day to 120 Years, 1000 participants planned.

Enrollment status: Open now. The study started 12 July 2024 and is expected to finish 27 June 2054.

Contact: eyeGene Coordinating Center, (301) 435-3032, neieyegeneinfo@nih.gov.

Source: ClinicalTrials.gov, NCT06491615 (https://clinicaltrials.gov/study/NCT06491615).

Start date: July 12, 2024

Completion date: June 27, 2054

Organizer: National Eye Institute (NEI)

Contact: eyeGene Coordinating Center, (301) 435-3032

Tel.: (301) 435-3032

Email: neieyegeneinfo@nih.gov

Link: https://clinicaltrials.gov/study/NCT06491615

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases . By submitting you agree to our Privacy Policy.

FAQOther Questions